2 April 2026
Merck starts pivotal Phase 2b/3 trial of MK-8748 (Tiespectus) for neovascular AMD
Pivotal Phase 2b/3 MALBEC trial begins for a bispecific Tie2 agonist/VEGF inhibitor in neovascular AMD; randomized vs aflibercept, primary endpoint mean BCVA change at Year 1.
